Guggenheim initiated coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research note issued to investors on Monday, BenzingaRatingsTable reports. The firm issued a buy rating on the stock.
Other research analysts have also issued reports about the stock. Morgan Stanley began coverage on shares of Genmab A/S in a research report on Monday. They issued an overweight rating for the company. Royal Bank of Canada began coverage on shares of Genmab A/S in a research report on Monday. They issued an outperform rating and a $23.00 target price for the company.
Shares of NASDAQ:GMAB opened at $19.89 on Monday. Genmab A/S has a 52-week low of $12.10 and a 52-week high of $21.45.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Read More: Bollinger Bands
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.